AstraZeneca PLC is 65.9x more valuable than Travere Therapeutics, Inc. by market capitalization ($286.27 B vs $4.35 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | TVTX | AZN |
|---|---|---|
| Market cap | $4.35 B | $286.27 B |
| US-listed rank | #1502 | #45 |
| Revenue (latest FY) | $490.73M | - |
| Net income (latest FY) | -$25.55M | - |
| Net margin | -5.2% | - |
| SEC filings | 1,240 | 1,004 |
AstraZeneca PLC is 65.9x more valuable than Travere Therapeutics, Inc. by market capitalization ($286.27 B vs $4.35 B).
Full pages: Travere Therapeutics, Inc. and AstraZeneca PLC, or browse the full rankings.